Terns Pharmaceuticals Valuation
| TERN Stock | USD 4.64 0.46 11.00% |
At this time, the company appears to be undervalued. Terns Pharmaceuticals has a current Real Value of $8.16 per share. The regular price of the company is $4.64. Our model measures the value of Terns Pharmaceuticals from inspecting the company fundamentals such as Shares Owned By Institutions of 97.80 %, shares outstanding of 84.94 M, and Return On Equity of -0.28 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Terns Pharmaceuticals' valuation include:
Price Book 1.0394 | Enterprise Value | Enterprise Value Ebitda (5.80) | Price Sales 302.636 | Enterprise Value Revenue 337.4686 |
Undervalued
Today
Please note that Terns Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Terns Pharmaceuticals is based on 3 months time horizon. Increasing Terns Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Terns Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Terns Stock. However, Terns Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.64 | Real 8.16 | Target 19.06 | Hype 4.0 | Naive 4.98 |
The intrinsic value of Terns Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Terns Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Terns Pharmaceuticals helps investors to forecast how Terns stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Terns Pharmaceuticals more accurately as focusing exclusively on Terns Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Terns Pharmaceuticals' intrinsic value based on its ongoing forecasts of Terns Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Terns Pharmaceuticals' closest peers.
Terns Pharmaceuticals Cash |
|
Terns Valuation Trend
Knowing Terns Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Terns Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Terns Pharmaceuticals Total Value Analysis
Terns Pharmaceuticals is at this time projected to have valuation of 7.36 M with market capitalization of 378.83 M, debt of 603 K, and cash on hands of 139.81 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Terns Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.36 M | 378.83 M | 603 K | 139.81 M |
Terns Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Terns is to check how much profit was generated for every dollar of assets it reports. Terns Pharmaceuticals has a negative utilization of assets of -0.19 %, losing $0.001923 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Terns Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Terns Pharmaceuticals Ownership Allocation
Terns Pharmaceuticals shows a total of 84.94 Million outstanding shares. The majority of Terns Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Terns Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Terns Pharmaceuticals. Please pay attention to any change in the institutional holdings of Terns Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Terns Pharmaceuticals Profitability Analysis
Net Loss for the year was (90.21 M) with profit before overhead, payroll, taxes, and interest of 1000 K.About Terns Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Terns Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Terns Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Terns Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Terns Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Terns Pharmaceuticals. We calculate exposure to Terns Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Terns Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -792.9 K | -753.3 K | |
| Pretax Profit Margin | (44.68) | (46.92) | |
| Operating Profit Margin | (44.87) | (47.12) | |
| Net Loss | (45.14) | (47.40) | |
| Gross Profit Margin | 0.44 | 0.39 |
Terns Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 71.3 M |
Terns Pharmaceuticals Current Valuation Indicators
Terns Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Terns Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Terns Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Terns Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Terns Pharmaceuticals' worth.When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.